Weekly topotecan and biweekly bevacizumab in recurrent and progressive ovarian carcinoma: A single institution experience for third-line or greater treatment.
Kassondra S Grzankowski
No relevant relationships to disclose
Shashikant B. Lele
No relevant relationships to disclose
John Pietkiewicz
No relevant relationships to disclose